Omnicell Financials

OMCL Stock  USD 38.06  0.41  1.07%   
Omnicell is doing better financially today then in previous quarter. It has a moderate odds of reporting better financial numbers in April. At this time, Omnicell's Current Deferred Revenue is quite stable compared to the past year. Net Debt is expected to rise to about 2.8 M this year, although the value of Other Liabilities will most likely fall to about 33.7 M. Key indicators impacting Omnicell's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio2.631.369
Way Up
Pretty Stable
The essential information of the day-to-day investment outlook for Omnicell includes many different criteria found on its balance sheet. An individual investor should monitor Omnicell's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Omnicell.

Net Income

17.62 Million

  

Omnicell Earnings Geography

Omnicell Stock Summary

Omnicell competes with HealthStream, National Research, Forian, Definitive Healthcare, and Evolent Health. Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California. Omnicell operates under Health Information Services classification in the United States and is traded on NASDAQ Exchange. It employs 4000 people.
Specialization
Health Care, Health Care Equipment & Services
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS68213N1090
CUSIP68213N109
LocationCalifornia; U.S.A
Business Address4220 North Freeway,
SectorHealth Care Technology
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.omnicell.com
Phone877 415 9990
CurrencyUSD - US Dollar

Omnicell Key Financial Ratios

Omnicell Key Balance Sheet Accounts

202020212022202320242025 (projected)
Total Assets1.8B2.1B2.2B2.2B2.1B2.2B
Other Current Liab113.4M179.4M344.7M177.8M402.5M422.7M
Other Liab57.9M64.5M79.7M46.2M53.1M33.7M
Net Debt30.2M179.0M286.4M146.1M2.6M2.8M
Retained Earnings290.7M368.6M390.7M370.4M382.9M402.0M
Accounts Payable40.3M71.5M63.4M45.0M51.8M26.3M
Cash485.9M349.1M330.4M468.0M369.2M387.7M
Long Term Debt50M467.2M566.6M569.7M166.4M176.3M
Net Receivables190.1M240.9M299.5M263.9M256.4M269.2M
Inventory96.3M119.9M147.5M110.1M88.7M54.0M
Other Current Assets57.1M70.8M104.4M85.6M101.2M106.3M
Total Liab857.0M995.8M1.1B1.0B877.6M921.5M
Total Current Assets829.4M780.7M881.8M927.6M815.5M856.3M
Short Term Debt(55.4M)501.1M10.8M10.5M12.1M11.5M
Common Stock53K54K55K56K57K54.2K
Other Assets100.7M268.5M225.6M139.0M159.8M167.8M
Good Will499.3M738.9M734.3M735.8M734.7M771.5M
Intangible Assets168.2M277.6M242.9M277.8M188.3M103.8M
Net Tangible Assets845.3M967.5M130.2M153.0M175.9M297.7M
Capital Surpluse780.9M920.4M1.0B1.0B1.2B729.3M

Omnicell Key Income Statement Accounts

202020212022202320242025 (projected)
Interest Expense2.1M22.4M130K14.8M25.3M26.5M
Total Revenue892.2M1.1B1.3B1.1B1.1B1.2B
Gross Profit413.3M554.7M589.0M496.8M471.0M257.7M
Operating Income35.5M89.5M(2.3M)(34.9M)337K320.2K
Ebit35.5M89.5M(2.3M)(34.9M)(40.1M)(38.1M)
Research Development70.2M75.7M105.0M97.1M90.4M94.9M
Ebitda107.1M174.4M96.8M(34.9M)337K320.2K
Cost Of Revenue478.9M577.4M707.0M650.3M641.2M673.3M
Income Before Tax29.3M66.0M(2.5M)(20.1M)25.6M19.1M
Net Income32.2M77.8M5.6M(20.4M)12.5M17.6M
Income Tax Expense(2.8M)(11.8M)(8.1M)263K13.1M13.7M
Tax Provision(2.8M)(11.8M)(8.1M)(2.7M)13.1M13.7M
Net Interest Income(6.2M)(23.5M)(130K)12.8M25.3M26.5M

Omnicell Key Cash Accounts

202020212022202320242025 (projected)
Change To Inventory12.4M(25.7M)(30.1M)38.0M5.4M5.7M
Change In Cash362.7M(134.3M)(2.8M)148.1M(102.4M)(97.2M)
Free Cash Flow131.0M173.5M17.0M126.1M151.3M158.8M
Depreciation71.6M84.9M99.2M95.6M89.8M94.2M
Other Non Cash Items6.6M22.5M15.5M18.0M61.0M64.0M
Capital Expenditures54.9M58.3M60.7M55.0M36.5M25.8M
Net Income32.2M77.8M5.6M(20.4M)12.5M17.6M
End Period Cash Flow489.9M355.6M352.8M501.0M398.6M418.5M
Investments(279.9M)(412.5M)(58.7M)(59.9M)(52.8M)(55.4M)
Change Receivables(25.2M)34.0M(37.6M)(75.7M)(68.1M)(64.7M)
Change To Netincome33.2M38.4M50.3M31.6M36.4M21.5M

Omnicell Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Omnicell's current stock value. Our valuation model uses many indicators to compare Omnicell value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Omnicell competition to find correlations between indicators driving Omnicell's intrinsic value. More Info.
Omnicell is regarded fourth in return on equity category among its peers. It is rated below average in return on asset category among its peers reporting about  0.28  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Omnicell is roughly  3.55 . At this time, Omnicell's Return On Equity is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Omnicell by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Omnicell Systematic Risk

Omnicell's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Omnicell volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Omnicell correlated with the market. If Beta is less than 0 Omnicell generally moves in the opposite direction as compared to the market. If Omnicell Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Omnicell is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Omnicell is generally in the same direction as the market. If Beta > 1 Omnicell moves generally in the same direction as, but more than the movement of the benchmark.

Omnicell Thematic Clasifications

Omnicell is part of Computers investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Computers industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
ComputersView
This theme covers USA Equities from Computers industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Today, most investors in Omnicell Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Omnicell's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Omnicell growth as a starting point in their analysis.

Price Earnings To Growth Ratio

(1.07)

At this time, Omnicell's Price Earnings To Growth Ratio is quite stable compared to the past year.

Omnicell March 1, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Omnicell help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Omnicell. We use our internally-developed statistical techniques to arrive at the intrinsic value of Omnicell based on widely used predictive technical indicators. In general, we focus on analyzing Omnicell Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Omnicell's daily price indicators and compare them against related drivers.
When determining whether Omnicell is a strong investment it is important to analyze Omnicell's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Omnicell's future performance. For an informed investment choice regarding Omnicell Stock, refer to the following important reports:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Omnicell. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
For more information on how to buy Omnicell Stock please use our How to buy in Omnicell Stock guide.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Health Care Technology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Omnicell. If investors know Omnicell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Omnicell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.558
Earnings Share
0.27
Revenue Per Share
24.154
Quarterly Revenue Growth
0.186
Return On Assets
0.0029
The market value of Omnicell is measured differently than its book value, which is the value of Omnicell that is recorded on the company's balance sheet. Investors also form their own opinion of Omnicell's value that differs from its market value or its book value, called intrinsic value, which is Omnicell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Omnicell's market value can be influenced by many factors that don't directly affect Omnicell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Omnicell's value and its price as these two are different measures arrived at by different means. Investors typically determine if Omnicell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Omnicell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.